Skip to main content
Equibles
ARVN logo

ARVN · Arvinas, Inc.

Track ARVN — free

Use ARVN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ARVN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.97 -0.04 (-0.44%) At close · Aug 14
Market Cap
$582.59M
Shares
65.39M

Arvinas, Inc. Earnings Call Transcripts

Every quarterly earnings call for Arvinas, Inc. (ARVN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲196% $102.40M −$49.20M '24 Q3 24-10-30 · $59.20M −$45.10M '24 Q4 25-02-11 ▲646.2% $188.80M $82.90M '25 Q1 25-05-01 ▼70.7% $22.40M −$61.20M '25 Q2 25-08-06 ▼59.1% $41.90M −$35.10M '25 Q3 25-11-05 ▼84% $9.50M −$67.40M '25 Q4 26-02-24 ▼91.7% $15.60M −$57.60M '26 Q1 26-05-12 LATEST ▲1014.7% $249.70M $169.40M '26 Q2 26-08-04
Earnings call
FY26 · Q2
2026-08-04
Arvinas, Inc. Q2 FY2026 Earnings Call
Revenue
$249.70M
▲ 1014.7% YoY
Diluted EPS
$2.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Arvinas, Inc. Q1 FY2026 Earnings Call
Confident tone ARV-102 in PSP / Parkinson's Pipeline and PROTAC platform KRAS G12D degrader (ARV-806)
Revenue
$15.60M
▼ 91.7% YoY
Diluted EPS
$-0.90
▼ 178.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Arvinas, Inc. Q4 FY2025 Earnings Call
Confident tone ARV-102 LRRK2 degrader in Parkinson's and PSP Regulatory interactions and registrational path ARV-806 KRAS G12D PROTAC
Revenue
$9.50M*
▼ 84% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Arvinas, Inc. Q3 FY2025 Earnings Call
Confident tone ARV-102 LRRK2 degrader ARV-393 BCL6 degrader ARV-806 KRAS G12D degrader
Revenue
$41.90M
▼ 59.1% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Arvinas, Inc. Q2 FY2025 Earnings Call
Positive tone Vepdeg/Pfizer collaboration uncertainty PROTAC pipeline progression LRRK2 degrader ARV-102 in neuroscience
Revenue
$22.40M
▼ 70.7% YoY
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Arvinas, Inc. Q1 FY2025 Earnings Call
Positive tone VEPDEG VERITAC-2 pivotal data and regulatory filing Pfizer joint development plan changes Second-line ESR1 mutant market opportunity
Revenue
$188.80M
▲ 646.2% YoY
Diluted EPS
$1.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Arvinas, Inc. Q4 FY2024 Earnings Call
Confident tone Phase 3 combination trials in 1L and 2L Vepdegestrant (vepdeg) ER degrader program VERITAC-2 Phase 3 trial
Revenue
$59.20M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Arvinas, Inc. Q3 FY2024 Earnings Call
Positive tone Vepdeg combination strategy (TACTILE/VERITAC-3) Pfizer partnership and commercialization transition ARV-102 neuroscience / LRRK2
Revenue
$102.40M
▲ 196% YoY
Diluted EPS
$-0.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–9 of 9 earnings calls
Key facts CIK 1655759 CUSIP 04335A105 13F (30d) 193 filings 192 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)